Sexual impairment in patients with hidradenitis suppurativa: a systematic review
- PMID: 32531099
- DOI: 10.1111/jdv.16726
Sexual impairment in patients with hidradenitis suppurativa: a systematic review
Abstract
Hidradenitis suppurativa (HS) can cause considerable impact on several aspects of quality of life. Sexuality is a central aspect of quality of life. In recent years, there has been an increase in the number of articles on HS and sexuality. To achieve our aim of synthesizing the available scientific evidence on HS and sexual health, we conducted a systematic review in February 2020. The clinical databases used included Medline and Embase. All types of epidemiological articles were included; reviews, guidelines, protocols, conference abstracts and case report articles were excluded. Eleven studies were included for review, representing 42 729 patients with HS. The most common study design was cross-sectional with or without comparison group(s), conducted in an outpatient setting or through surveys. Prevalence of sexual dysfunction ranged between 51-62%, and in the case of erectile dysfunction, a specific kind of sexual dysfunction affecting penile erection, it ranged from between 52% and 60% of patients studied using validated questionnaires. Potential risk factors for sexual dysfunction among men and women were identified, mainly related to disease activity, symptoms and partners. Mood disorders like depression and anxiety appear to be associated with sexual dysfunction. Women were more affected by sexual distress. HS patients with sexual dysfunction had a decreased overall quality of life. With respect to treatment, surgery did not improve sexual function and there is no scientific evidence regarding medical treatments. Patients stated that they would like to treat their sexual problems with healthcare professionals. In conclusion, sexual and erectile dysfunction are common in HS patients, and negatively affect their quality of life. There are clinical factors potentially associated with this which should be identified and treated by dermatologists in the comprehensive care of HS patients. Prospective studies are needed to provide more scientific evidence on this unmet need.
© 2020 European Academy of Dermatology and Venereology.
Comment in
-
Male and Female Sexual Function and Dysfunction; Andrology.J Urol. 2021 Dec;206(6):1501-1503. doi: 10.1097/JU.0000000000002223. Epub 2021 Sep 9. J Urol. 2021. PMID: 34496601 No abstract available.
References
-
- Kurzen H, Kurokawa I, Jemec GB et al. What causes Hidradenitis suppurativa? Exp Dermatol 2008; 17: 455-456; discussion 457-472.
-
- Molina-Leyva A, Cuenca-Barrales C. Pruritus and malodour in patients with Hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology (Basel, Switzerland) 2020; 236: 59-65.
-
- Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with Hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
-
- Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of Hidradenitis suppurativa. Br J Dermatol 2018; 178: 917-924.
-
- Zouboulis CC, Desai N, Emtestam L et al. European S1 guideline for the treatment of Hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-644.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
